{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:55:18Z","timestamp":1792166118269,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.esmoop.2025.105096","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T14:39:37Z","timestamp":1747060777000},"page":"105096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58\u2013UCGI35\u2013REGIRI Unicancer randomised phase II study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6997-6090","authenticated-orcid":false,"given":"E.","family":"Samalin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Evesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-5693","authenticated-orcid":false,"given":"C.","family":"De La Fouchardiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Khemissa-Akouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3743","authenticated-orcid":false,"given":"O.","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6412-932X","authenticated-orcid":false,"given":"M.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dermeche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Botsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-9635","authenticated-orcid":false,"given":"D.","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zaanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ben Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Guardiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-0423","authenticated-orcid":false,"given":"O.","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Le Brun Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-8783","authenticated-orcid":false,"given":"S.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sefrioui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-0212","authenticated-orcid":false,"given":"T.","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"De Sousa Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8261-3470","authenticated-orcid":false,"given":"E.","family":"Crapez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Castan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Senellart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.105096_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study","volume":"47","author":"Morgan","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105096_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11894-016-0506-0","article-title":"Gastric cancer: how can we reduce the incidence of this disease?","volume":"18","author":"den Hoed","year":"2016","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.esmoop.2025.105096_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105096_bib4","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/1055-9965.EPI-13-1057","article-title":"Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention","volume":"23","author":"Karimi","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105096_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11894-017-0575-8","article-title":"Changing trends in stomach cancer throughout the world","volume":"19","author":"Balakrishnan","year":"2017","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.esmoop.2025.105096_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/tgh.2017.01.07","article-title":"Regorafenib in gastric cancer","volume":"2","author":"Smyth","year":"2017","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"10251","key":"10.1016\/j.esmoop.2025.105096_bib7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"issue":"10418","key":"10.1016\/j.esmoop.2025.105096_bib8","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"issue":"9742","key":"10.1016\/j.esmoop.2025.105096_bib9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"10294","key":"10.1016\/j.esmoop.2025.105096_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105096_bib11","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10302","key":"10.1016\/j.esmoop.2025.105096_bib12","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2025.105096_bib13","first-page":"CD004064","article-title":"Chemotherapy for advanced gastric cancer","volume":"8","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105096_bib14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S2468-1253(19)30083-4","article-title":"Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial","volume":"4","author":"Yamada","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105096_bib15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105096_bib16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.esmoop.2025.105096_bib17","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2013.54.1011","volume":"32","author":"Guimbaud","year":"2014","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.esmoop.2025.105096_bib18","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105096_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00280-012-2027-3","article-title":"A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil\/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy","volume":"71","author":"Sym","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105096_bib20","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","article-title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"47","author":"Thuss-Patience","year":"2011","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105096_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamaoncol.2024.0207","article-title":"FOLFIRI plus durvalumab with or without tremelimumab in second-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: the PRODIGE 59-FFCD 1707-DURIGAST randomized clinical trial","volume":"10","author":"Tougeron","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105096_bib22","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1002\/onco.13623","article-title":"Tumor response and symptom palliation from RAINBOW, a phase III trial of ramucirumab plus paclitaxel in previously treated advanced gastric cancer","volume":"26","author":"Cascinu","year":"2021","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105096_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5230\/jgc.2017.17.e16","article-title":"Prognostic factor analysis of overall survival in gastric cancer from two phase III studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data","volume":"17","author":"Fuchs","year":"2017","journal-title":"J Gastric Cancer"},{"issue":"9911","key":"10.1016\/j.esmoop.2025.105096_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105096_bib25","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105096_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.078","volume":"34","author":"Zaanan","year":"2023","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2025.105096_bib27","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2015.65.1901","article-title":"Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial","volume":"34","author":"Pavlakis","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105096_bib28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.24.00055","article-title":"INTEGRATE iia phase III study: regorafenib for refractory advanced gastric cancer","volume":"43","author":"Pavlakis","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105096_bib29","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/annonc\/mdt056","article-title":"Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study","volume":"24","author":"Schultheis","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105096_bib30","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/bjc.2013.813","article-title":"Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I\/II trial","volume":"110","author":"Samalin","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105096_bib31","first-page":"301","article-title":"Sorafenib plus irinotecan combination in patients with RAS-mutated metastatic colorectal cancer refractory to standard combined chemotherapies: a multicenter, randomized phase 2 trial (NEXIRI-2\/PRODIGE 27)","volume":"19","author":"Samalin","year":"2020","journal-title":"Clin Colorectal Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105096_bib32","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41431-023-01315-x","article-title":"Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan","volume":"31","author":"Hulshof","year":"2023","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105096_bib33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1479-7364-4-4-238","article-title":"The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions","volume":"4","author":"Marques","year":"2010","journal-title":"Hum Genomics"},{"key":"10.1016\/j.esmoop.2025.105096_bib34","first-page":"61","article-title":"UGT1A1 polymorphisms in cancer: impact on irinotecan treatment","volume":"10","author":"Takano","year":"2017","journal-title":"Pharmgenomics Pers Med"},{"issue":"10064","key":"10.1016\/j.esmoop.2025.105096_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.esmoop.2025.105096_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.esmoop.2025.105096_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105096_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105096_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/jjco\/hyh006","article-title":"Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy","volume":"34","author":"Chun","year":"2004","journal-title":"Jpn J Clin Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105096_bib40","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","article-title":"Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone","volume":"30","author":"Kang","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105096_bib41","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s10120-017-0742-5","article-title":"Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population","volume":"21","author":"Warschkow","year":"2018","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.esmoop.2025.105096_bib42","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/1471-2407-11-496","article-title":"Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer","volume":"11","author":"Dahan","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2025.105096_bib43","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2019.09.015","article-title":"Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study","volume":"123","author":"Ducreux","year":"2019","journal-title":"Eur J Cancer"},{"issue":"43","key":"10.1016\/j.esmoop.2025.105096_bib44","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.3748\/wjg.v21.i43.12234","article-title":"Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer","volume":"21","author":"Fujita","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105096_bib45","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3892\/mco.2017.1145","article-title":"Response to regorafenib at an initial dose of 120 mg as salvage therapy for metastatic colorectal cancer","volume":"6","author":"Osawa","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105096_bib46","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.2147\/OTT.S156760","article-title":"Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials","volume":"11","author":"Yin","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105096_bib47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10637-012-9820-z","article-title":"Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer","volume":"31","author":"Azad","year":"2013","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105096_bib48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2006.08.032","article-title":"Results from an in vitro and a clinical\/pharmacological phase I study with the combination irinotecan and sorafenib","volume":"43","author":"Mross","year":"2007","journal-title":"Eur J Cancer"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105096_bib49","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2008.19.0314","article-title":"Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan","volume":"27","author":"Cecchin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105096_bib50","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2022.03.009","article-title":"Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study","volume":"168","author":"Rousseau","year":"2022","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105096_bib51","doi-asserted-by":"crossref","first-page":"e642","DOI":"10.1093\/oncolo\/oyac086","article-title":"Phase II study of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with advanced gastric cancer: HGCSG1603","volume":"27","author":"Kawamoto","year":"2022","journal-title":"Oncologist"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T07:47:30Z","timestamp":1757576850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925009652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2059702925009652"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105096","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58\u2013UCGI35\u2013REGIRI Unicancer randomised phase II study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105096"}}